SOURCE: HealthSonix

September 19, 2006 16:05 ET

HealthSonix to Begin Trading in Europe on the Frankfurt Exchange

IRVINE, CA -- (MARKET WIRE) -- September 19, 2006 -- HealthSonix Inc. (PINKSHEETS: HSXI) today announced that it has received final approval from Deutsche Börse AG and its shares will be available for trading through the "Xetra" Frankfurt Stock Exchange, the third largest exchange in the world. The trading symbol is H7S and the German ISIN code is US42226Q1022.

RG SECURITIES AG, a major German investment banking and brokerage firm, facilitated the Frankfurt listing. RG SECURITIES will also act as the Company's market maker and a local specialist on the German exchange.

"There is worldwide interest in our medical technology and positive clinical results to date. Demand for our products is expected to be very high in Europe, especially in Germany. It is a natural progression for us to facilitate international trading in HealthSonix shares through this listing on the Frankfurt Exchange," added HealthSonix Chairman of the Board, Mr. Ivan X. de Souza. "Being on a major German stock exchange is a part of our company's overall strategy to boost our status as an emerging global medical technology company."

The Frankfurt Stock Exchange (German: FWB R Frankfurter Wertpapierbörse) is the largest stock exchange in Germany. It is owned and operated by Deutsche Börse AG, which also owns the European futures exchange, EUREX, and the Clearstream clearing company. The Frankfurt Stock Exchange executes over 90 percent of the transactions in the German market and represents a substantial share of the overall European market.

HealthSonix Inc. (PINKSHEETS: HSXI) (XETRA: H7S) is a publicly traded medical technology company. The Company's core offerings are based on proprietary, patent pending medical technologies that use sound pressure waves to administer sub-sensory micro vibration to the human body. Precisely formatted low frequency sound pressure waves are 80% effective in treating the pain of many diseases, particularly arthritis. All treatments and products are safe, non-invasive, drug free, and have no known side effects.

More information regarding HealthSonix and its products and services can be found on the World Wide Web at: www.HealthSonix.com or by calling the company at 1-877-622-2121.

Note: A number of statements contained in this report are forward-looking statements, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, competitive market conditions, successful integration of acquisitions, the ability to secure additional sources of financing, the ability to reduce operating expenses and other factors not set forth herein. The actual results that the Company may achieve may differ materially from any forward-looking statements due to such risks and uncertainties.

Contact Information